Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | VNN1 | O95497 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | ITGA1 | P56199 | 2/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.45 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.45 |
| ▸ | FEN1 | P39748 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3445668 | 0.90 | PARP1 (0.63) | PARP1ATMTDP1L3MBTL1VNN1 | |
| SCHEMBL3177794 | 0.86 | PARP1 (0.59) | PARP1ATMTDP1L3MBTL1ALOX15 | |
| SCHEMBL3173817 | 0.86 | PARP1 (0.68) | PARP1ATMTDP1L3MBTL1VNN1 | |
| SCHEMBL31514279 | 0.84 | ATM (0.71) | PARP1ATMTDP1L3MBTL1VNN1 | |
| SCHEMBL1133114 | 0.84 | ATM (0.71) | PARP1ATMTDP1L3MBTL1VNN1 | |
| SCHEMBL3444927 | 0.84 | PARP1 (0.65) | PARP1ATMTDP1L3MBTL1VNN1 | |
| SCHEMBL8437706 | 0.83 | SRD5A2 (0.64) | PARP1ATMTDP1L3MBTL1ALOX15 | |
| SCHEMBL7488057 | 0.83 | MAPK1 (0.64) | PARP1ATMTDP1L3MBTL1ALOX15 | |
| SCHEMBL3845298 | 0.82 | ATM (0.56) | ATMTDP1L3MBTL1ITGA1ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL28227232 | 0.82 | ATM (0.68) | PARP1ATMTDP1L3MBTL1VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210617-A1 | Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-08-19 | — | — | US | disclosed |
| EP-1904451-A1 | ARYL-ALKYLAMINES AND HETEROARYL-ALKYLAMINES AS PROTEIN KINASE INHIBITORS | Astex Therapeutics Limited (GB) | 2008-04-02 | — | — | EP | disclosed |
| WO-2006136830-A1 | ARYL-ALKYLAMINES AND HETEROARYL-ALKYLAMINES AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210617-A1 | Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors | ERBB2, ABL1, GRK2 | PARP1 3137/4885ATM 1043/4885TDP1 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.